Press Releases about Harrow Inc
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20230223005967/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
![](https://mms.businesswire.com/media/20230223005365/en/827144/22/Schall-Firm-Logo-640x360.jpg)
![](https://mms.businesswire.com/media/20230222006009/en/827144/22/Schall-Firm-Logo-640x360.jpg)
![](https://mms.businesswire.com/media/20230222005945/en/1164042/5/July_30%2C_2021_-_ROSEN_LOGO.jpg)
![](https://mms.businesswire.com/media/20230214005889/en/1533746/5/Harrow_logo_wTag.jpg)
Harrow Launches Next-Generation Compounded Atropine Formulations
February 15, 2023
From Harrow
Via Business Wire
![](https://mms.businesswire.com/media/20230202005395/en/1533746/5/Harrow_logo_wTag.jpg)
![](https://mms.businesswire.com/media/20230123005117/en/1533746/5/Harrow_logo_wTag.jpg)
![](https://mms.businesswire.com/media/20230105005349/en/1677676/5/Fortisite_bottle_for_Release.jpg)
From Harrow Health, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20221221005126/en/1153481/5/MELT_logo.jpg)
![](https://mms.businesswire.com/media/20221215006100/en/1533746/5/Harrow_logo_wTag.jpg)
Harrow Secures Capital to Close Recently Announced Acquisition
December 16, 2022
From Harrow Health, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20221213005828/en/1533746/5/Harrow_logo_wTag.jpg)
![](https://mms.businesswire.com/media/20221213005819/en/1533746/5/Harrow_logo_wTag.jpg)
![](https://mms.businesswire.com/media/20221213005815/en/1533746/5/Harrow_logo_wTag.jpg)
![](https://mms.businesswire.com/media/20221130005317/en/1533746/5/Harrow_logo_wTag.jpg)
Harrow and iOR Partners Expand National Product Supply Agreement
November 30, 2022
From Harrow
Via Business Wire
![](https://mms.businesswire.com/media/20221114005902/en/1533746/5/Harrow_logo_wTag.jpg)
Harrow Announces Third Quarter 2022 Financial Results
November 14, 2022
From Harrow
Via Business Wire
![](https://mms.businesswire.com/media/20221109006116/en/1632481/5/atropineDOTcom_%2B_imprimis_logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20221027005179/en/1533746/5/Harrow_logo_wTag.jpg)
From Harrow
Via Business Wire
![](https://mms.businesswire.com/media/20221027005245/en/1153481/5/MELT_logo.jpg)
![](https://mms.businesswire.com/media/20221005005735/en/1593274/5/BW_Harrow_logo_CMYK_wTag_w%28R%29.jpg)
![](https://mms.businesswire.com/media/20220929005297/en/1153480/4/imprimisRx-logo.jpg)
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
September 29, 2022
From Harrow
Via Business Wire
![](https://mms.businesswire.com/media/20220927005982/en/1533746/5/Harrow_logo_wTag.jpg)
![](https://mms.businesswire.com/media/20220811005152/en/1533746/5/Harrow_logo_wTag.jpg)
![](https://mms.businesswire.com/media/20220809005923/en/1533746/5/Harrow_logo_wTag.jpg)
Harrow Health Announces Second Quarter 2022 Financial Results
August 09, 2022
From Harrow Health, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20220727005305/en/1153477/5/HROW_Logo.jpg)
![](https://mms.businesswire.com/media/20220624005018/en/1153477/5/HROW_Logo.jpg)
![](https://mms.businesswire.com/media/20220505006029/en/1153477/5/HROW_Logo.jpg)
From Harrow Health, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20220503006359/en/1153481/5/MELT_logo.jpg)
![](https://mms.businesswire.com/media/20220422005283/en/1153477/5/HROW_Logo.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.